New priority review, Incyte’s zilurgisertib moves closer to rare-disease approval

Oral candidate zilurgisertib from Mirum and Incyte has delivered pivotal Phase 2 data in fibrodysplasia ossificans progressiva, earning FDA priority review and putting the small-molecule therapy on a fast track toward a potential first approval for patients 12 and older.

Edited by ad hoc news Flagship & Bestseller Desk. Reviewed before publication on 06/15/2026 at 3:36 PM ET. Details in the imprint.

Oral rare-disease candidate zilurgisertib, developed by Mirum Pharmaceuticals and Incyte, has taken a major regulatory step: the US Food and Drug Administration has accepted the New Drug Application and granted priority review for use in fibrodysplasia ossificans progressiva (FOP) in patients 12 years and older. The move follows pivotal Phase 2 results from the PROGRESS study showing strong reductions in heterotopic ossification lesions and flare activity over 24 to 48 weeks in adolescents and adults with this ultra-rare condition, positioning zilurgisertib as a potential first-in-class treatment if approved.

What the PROGRESS data show for zilurgisertib in FOP

Zilurgisertib is an investigational oral small-molecule therapy designed to inhibit a signaling pathway that drives abnormal bone formation in FOP, a disease in which soft tissues gradually turn into bone and severely limit mobility. In the pivotal Phase 2 PROGRESS study, Cohort 1 compared zilurgisertib with placebo and reported meaningful reductions in several key measures of disease activity, including total heterotopic ossification (HO) lesion volume, new HO lesions and flare events, according to a detailed joint announcement from Mirum and Incyte on June 14, 2026. The companies reported an 81% reduction in the proportion of patients developing new HO lesions at Week 24 versus placebo and a 99.9% reduction in total volume of new HO lesions for patients receiving zilurgisertib. Results also indicated that total existing HO lesion volume decreased in treated patients over 24 weeks, while it increased in the placebo group, and that no new lesions were observed in patients who continued on active treatment through Week 48 or crossed over from placebo at Week 24, suggesting durable disease control over nearly a year of therapy.

The same dataset highlighted that zilurgisertib’s effect on flare activity, another hallmark of FOP progression, was consistent with the imaging findings, with fewer and less severe flares compared with placebo-treated patients through the randomized portion of the trial. Clinical investigators presenting the data at the ENDO 2026 meeting noted that these outcomes were seen across adolescents and adults enrolled in Cohort 1, despite the small numbers typical for a rare-disease study, and described the pattern of results as clinically meaningful for patients who currently have no approved targeted therapy for modifying the underlying disease process. Safety in PROGRESS was characterized as acceptable for a chronic rare-disease treatment, with the overall profile considered manageable in the context of the benefits observed, according to the conference presentation summary from the endocrine congress organizers. FirstWord Pharma’s coverage of the ENDO 2026 data emphasized that no new safety signals emerged in the pivotal cohort and that adverse events were generally consistent with prior studies of the molecule. These findings support plans to follow patients longer in the open-label extension and to further characterize long-term safety and durability of benefit as regulators review the NDA.

Regulatory momentum for zilurgisertib reflects the unmet need in FOP and the strength of the Phase 2 dataset. The FDA has granted the therapy priority review status, shortening the standard review timeline, and set a Prescription Drug User Fee Act (PDUFA) target action date of September 26, 2026, for its decision on the application, according to the same joint communication from Mirum and Incyte. Incyte highlights the FOP program as part of its broader rare-disease and inflammation portfolio, which complements its established hematology-oncology franchise centered on Jakafi and other targeted therapies. For patients and families affected by FOP, the regulatory timeline means a potential first approved oral treatment option could be available as soon as late 2026, subject to a positive decision, with Mirum leading commercial efforts in certain territories and Incyte positioned to benefit from milestones and royalties that would diversify its revenue mix beyond existing oncology products.

For Incyte, zilurgisertib sits alongside emerging assets such as novel antibodies and next-generation small molecules as the company works to extend its pipeline beyond Jakafi, which still generates the bulk of its product sales. Management has pointed to rare-disease programs as strategically important because they combine high unmet medical need with focused commercial footprints, potentially allowing for targeted investment and pricing that can support R&D returns. While specific peak sales expectations for zilurgisertib have not been disclosed, external analysts have flagged the program as a notable future contributor if the regulatory review is successful and label expansion to younger patients or earlier disease stages becomes possible over time.

In equity markets, Incyte shares trade on the NASDAQ under the symbol INCY and remain a bellwether for investor sentiment on the company’s transition from a single-product-heavy portfolio to a broader mix driven by newer launches and partnered assets such as zilurgisertib. According to recent market data, Incyte’s stock closed at $108.53 on NASDAQ on 06/12/2026, reflecting a gain of nearly 10% since the start of the year as the pipeline has delivered a series of clinical and regulatory updates. MarketBeat lists the company’s shares under ISIN US45337C1027 and categorizes it in the biotechnology segment. For now, the upcoming FDA decision on zilurgisertib represents one of the next major milestones that could influence how investors view the balance between Incyte’s established revenue base and its pipeline-driven growth prospects.

Zilurgisertib in brief: key facts for investors and patients

• Product: Zilurgisertib
• Manufacturer: Incyte Corporation / Mirum Pharmaceuticals, Inc.
• Category: Flagship rare-disease drug candidate
• Launch date: Not yet approved; FDA PDUFA target action date September 26, 2026
• MSRP / Price: Not available (investigational product)
• Availability: Available only through clinical trials such as the PROGRESS study
• Target audience: Adolescents and adults 12 years and older living with fibrodysplasia ossificans progressiva
• Key differentiator / USP: Oral small-molecule approach with pivotal Phase 2 data showing substantial reductions in new and existing heterotopic ossification lesions

This article was a.i.-assisted and editorially reviewed. Product information without warranty; prices and availability may change at short notice. Not investment advice and not a buy or sell recommendation. Trading involves risk up to and including the total loss of invested capital.